Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
Status:
Terminated
Trial end date:
2016-07-18
Target enrollment:
Participant gender:
Summary
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1,
cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin
(or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV).
2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV)
treatment using a new test of liver function, HepQuant-SHUNT.